DDX53 Regulates Cancer Stem Cell-Like Properties by Binding to SOX-2

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Cancer stem cells (CSCs) drive tumor growth and drug resistance.
• Cancer/testis antigen DDX53 is implicated in various cancers.
• CD133 is a known marker for cancer stem cells.

Purpose of the Study:

• To investigate the role of DDX53 in regulating cancer stem cell-like properties in melanoma.
• To explore the relationship between DDX53, SOX-2, and miR-200b in melanoma cells.
• To assess DDX53 as a potential immunotherapeutic target.

Main Methods:

• Co-expression analysis of DDX53 and CD133.
• Investigation of DDX53's regulation of SOX-2 in drug-resistant melanoma cells (Malme3M^R).
• Assessment of DDX53 and miR-200b involvement in tumor spheroid formation.
• Evaluation of DDX53's effect on self-renewal and tumorigenic potential of Malme3M^R-CD133 (+) cells.
• Use of a miR-200b inhibitor to study DDX53-SOX-2 interaction.

Main Results:

• DDX53 is co-expressed with CD133 in melanoma cells.
• DDX53 directly regulates SOX-2 expression in drug-resistant melanoma cells.
• DDX53 and miR-200b are involved in regulating tumor spheroid formation.
• DDX53 controls the self-renewal and tumorigenic potential of CD133-positive cells.
• Inhibition of miR-200b enhances DDX53's direct regulation of SOX-2.

Conclusions:

• DDX53 plays a critical role in maintaining cancer stem-like properties in melanoma.
• DDX53 regulates key stemness factors like SOX-2 and influences tumor initiation.
• DDX53 represents a promising immunotherapeutic target for overcoming melanoma stem cell characteristics and drug resistance.